Lyell Immunopharma (LYEL) Revenue (2020 - 2026)

Lyell Immunopharma has reported Revenue for 7 years, with the latest figure at $2000.0 in Q1 2026.

• Quarterly Revenue fell 71.43% year-over-year to $2000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $31000.0 (down 52.31% YoY) and the FY2025 annual result came in at $36000.0, down 40.98% from the prior year.
• Revenue fell to $2000.0 in Q1 2026 per LYEL's latest filing, from $6000.0 in the prior quarter.
• Over five years, Revenue peaked at $48.4 million in Q4 2022 and troughed at $2000.0 in Q1 2026.
• A 5-year average of $5.0 million and a median of $13000.0 in 2023 frame the typical range for Revenue.
• The sharpest annual moves came in 2022 and 2023: Revenue soared 1614.6% in 2022, then tumbled 99.97% in 2023.
• Over 5 years, Revenue stood at $48.4 million in 2022, then sank by 99.97% to $13000.0 in 2023, then decreased by 15.38% to $11000.0 in 2024, then sank by 45.45% to $6000.0 in 2025, then slumped by 66.67% to $2000.0 in 2026.
• According to Business Quant data, Revenue over the past three periods registered $2000.0, $6000.0, and $15000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.